Methylgene Inc., of Montreal, presented Phase I data for MGCD290, an antifungal compound, showing that all doses and schedules of the drug were tolerated with no severe or serious adverse events, and that pharmacokinetics were dose dependent.
Suite: 1100 | Atlanta, Georgia 30346, USA
In the U.S. and Canada: 1-855-260-5607
Outside the U.S.: 1-646-822-4549
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter